Earnings ·
Lantheus Reports Q3 Revenue of $389.9M and Adjusted EPS of $1.68
LNTHLantheus Holdings, Inc.
Lantheus Holdings reported third-quarter worldwide revenue of $389.9 million, a 1.5% increase year-over-year, driven by growth in Neuraceq and DEFINITY sales offsetting a slight decline in PYLARIFY. GAAP fully diluted earnings per share were $0.33, while adjusted fully diluted EPS rose 32.3% to $1.68. The company also announced FDA approvals for TAUKLARIFY and BRAVNETSA. Lantheus is the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes.